Clinical trial
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
NCT00045006 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00045006 |
|---|---|
| Title | Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer |
| Official title | Phase I Clinical Trial of Oral Suberoylanilide Hydroxamic Acid - SAHA (MSK390) in Patients With Advanced Solid Tumors and Hematologic Malignancies |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | vorinostat |
| Start date | Jul 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Jul 1, 2008 |
| First posted | Jan 27, 2003 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: